Boeing stock heads into Monday after FAA moves 737 MAX 10 closer to approval — but a key snag remains

Boeing stock heads into Monday after FAA moves 737 MAX 10 closer to approval — but a key snag remains

NEW YORK, Jan 11, 2026, 18:06 EST — Market closed.

  • On Friday, Boeing shares closed at $234.53, marking a 3.1% increase.
  • The FAA has given the green light for Boeing’s 737 MAX 10 to enter a second phase of certification flight testing, though an engine deicing problem continues to shadow the program.
  • Boeing will release its fourth-quarter earnings on Jan. 27.

Boeing’s (BA.N) 737 MAX 10 edged closer to U.S. certification after the Federal Aviation Administration gave the green light for a second phase of flight testing, according to someone familiar with the program. This approval doesn’t extend to the smaller MAX 7, and an engine deicing problem affecting both models remains unresolved. “It’s progress, but until (the MAX 10) is certified, it’s not,” said aerospace analyst Scott Hamilton, principal at the Leeham Company. (Reuters)

The key point for BA stock right now is straightforward: investors see the MAX 10 timeline as a gauge of Boeing’s capacity to convert a hefty order backlog into actual deliveries and revenue. With over 1,200 orders waiting, the jet competes head-to-head with Airbus’ A321neo in the fiercely contested single-aisle segment. (Aviation News)

This step falls within the FAA’s Type Inspection Authorization (TIA) process, which allows the manufacturer to conduct certification flights under closer agency scrutiny. The MAX 10, designed for denser routes with seating near 230, faces delays partly due to engine anti-ice system modifications—a major technical snag affecting both the MAX 10 and MAX 7 models. Boeing declined to comment because of a pre-earnings quiet period, and the FAA also withheld details, according to Air Data News. (Air Data News)

Boeing shares ended Friday at $234.53, climbing 3.14% for the session, and were last seen near $234.35 in after-hours trading. (Wall Street Journal)

The broader market hit new highs to close the week, following a U.S. jobs report that revealed slower hiring alongside a dip in the unemployment rate to 4.4%, sustaining hopes for rate cuts. The S&P 500, Dow, and Nasdaq all recorded fresh all-time closes, Reuters reported. (Reuters)

For Boeing, the upcoming session hinges less on daily price moves and more on whether the certification story can withstand close examination. The FAA’s approval marks progress, but investors have watched “advances” slip into setbacks in the past.

Traders are closely monitoring how fast Boeing can deliver a straightforward solution to the deicing and anti-ice problem, as well as whether regulators speed up approvals for both the MAX 7 and MAX 10. Smooth progress would boost sentiment; delays would drag it down.

Still, the risk remains clear: if testing reveals fresh issues or the anti-ice modifications take longer than expected, certification delays could stretch further. That would push back initial deliveries and leave Boeing vulnerable to losing more ground in the single-aisle market. That’s typically when the stock gives up gains quickly.

Boeing faces a key event this week. The aerospace giant plans to unveil its fourth-quarter 2025 earnings Tuesday, Jan. 27. CEO Kelly Ortberg and CFO Jay Malave are set to discuss results during a 10:30 a.m. ET conference call. (Boeing Investors)

That report will probably shape investors’ patience — not only around the MAX 10 timeline, but also on production steadiness, delivery schedules, and the cash outlook management presents for 2026.

BA stock will respond to any fresh updates from the FAA and the perceived credibility of the certification timeline. The next key date to watch is Jan. 27.

Stock Market Today

  • Profound Medical: Top TSX Growth Stock Poised for Rapid Expansion, Q3 Revenues Surge 87%
    February 1, 2026, 9:22 PM EST. Profound Medical (TSX:PRN), a Canadian medical device firm specializing in MRI-guided ultrasound therapies, is highlighted as the sole TSX growth stock to hold for the next three years. The company reported an 87% revenue increase in Q3 to $5.3 million, driven by expanded installations of its flagship TULSA-PRO prostate cancer treatment system. Offering incision-free, MRI-guided ablation technology, Profound's procedures have gained Medicare approval with rising insurance reimbursements. Despite a net loss of $8 million, the company improved gross margins to 74.3% and ended Q3 with $25 million cash, supporting near-term liquidity. With 70 systems installed and 93 in advanced sales stages, Profound aims for 75 installations by year-end, making it a notable small-cap growth stock in healthcare on the TSX.
Trade Desk stock ends the week flat near $37 as CPI and earnings season set the next test
Previous Story

Trade Desk stock ends the week flat near $37 as CPI and earnings season set the next test

Lithium Americas (LAC) stock: U.S. critical-minerals push puts Thacker Pass back in focus next week
Next Story

Lithium Americas (LAC) stock: U.S. critical-minerals push puts Thacker Pass back in focus next week

Go toTop